{"schema_version":"secwatch.filing_event.v1","accession":"0001376339-23-000046","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.636914+00:00","generated_at":"2026-06-13T21:02:39.484614+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MiMedx suspends KOA program, focuses on wound care, raises 2023 sales guidance to mid-teens growth","bullets":["Suspending knee osteoarthritis program and disbanding Regenerative Medicine unit; President Dr. Stein departing.","Expects ~$25M annualized Adjusted EBITDA savings; one-time wind-down costs of ~$5M.","Raises 2023 net sales growth outlook from low-double digits to mid-teens.","Focus on Wound & Surgical business to drive profitability and cash flow.","Conference call at 5:30pm ET today to discuss strategic realignment."],"urls":{"canonical":"https://secwatch.observer/filing/0001376339-23-000046","json":"https://secwatch.observer/filing/0001376339-23-000046.json","markdown":"https://secwatch.observer/filing/0001376339-23-000046.md","text":"https://secwatch.observer/filing/0001376339-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000137633923000046/0001376339-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000137633923000046/mdxg-20230613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:02:39.484614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92615eb51e","claim":"Dr. Robert Stein departed as President of Regenerative Medicine business unit at MIMEDX GROUP, INC..","evidence_excerpt":"Dr. Robert Stein’s position as President of the Company’s Regenerative Medicine business unit was eliminated as part of the realignment, and he will be departing from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000137633923000046/0001376339-23-000046-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departing"},{"label":"Role","value":"President of Regenerative Medicine business unit"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}